InvestorsHub Logo
Followers 0
Posts 92
Boards Moderated 0
Alias Born 09/21/2016

Re: None

Friday, 03/18/2022 4:00:35 PM

Friday, March 18, 2022 4:00:35 PM

Post# of 5269
Further research reveals that AXIM originally was a cannabinoid biotech then transitioned with the purchase of Sapphire Biotech (Doug Lake) to an oncology focused biotech. The October 2020 letter to shareholders (patent and EUA applications) appears to been have been nothing more than a scratch off lottery ticket. Might be time for another shareholder letter from John H. so we can decide whether we should buy this one or not!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AXIM News